|
|
|
|
|
|
| About Renate Sekul (Graffinity) |
|
Dr. Renate Sekul received her Ph.D. in Biochemistry from the University of Cologne, Germany in 1989. After her thesis she joined Fournier Pharma in Germany as group leader for biochemistry and peptide synthesis. In 1998 she started at Graffinity, where she contributed to the development of the proprietary screening technology and was heading the biology group working in different drug discovery programs. Presently, she is VP R&D at Graffinity Pharmaceuticals, where her principal research interests include applications of SPR based screening.
|
|
Fragment based discovery by SPR imaging of chemical microarrays
Renate Sekul, VP R&D at Graffinity Pharmaceuticals, Germany
Fragment-based screening has evolved into a promising strategy in drug discovery. Surface plasmon resonance (SPR) is known to be a powerful tool for studying biomolecular interactions in a sensitive and label-free format. Graffinity´s SPR imaging of chemical microarrays can simultaneously generate affinity data for protein targets with up to 9,216 immobilized fragments per array. The detection sensitivity allows the identification of weak interactions and is therefore particularly suited for fragment screening. Selected case studies demonstrate the successful identification of low molecular weight inhibitors for pharmacologically relevant targets.
|
|
|
|
|
|
|
|
|
